Dr. Anthony Fauci is finally putting his weight behind an experimental new treatment for the SARS-CoV-2 virus that has obtained “amazing” results after nearly two years of a Covid-19 pandemic.
The director of the National Institute of Allergy and Infectious Diseases recently spoke out against molnupiravir, a Merck-made oral medication.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
Dr. Anthony Fauci, the president’s main medical adviser, praised the trial results as “amazing” and “extremely good news” at a press briefing on Friday.
A promising experimental drug from Merck, molnupiravir, has bolstered hopes of finding a simple at-home treatment for Covid-19.
— POLITICO (@politico) October 1, 2021
At the briefing, White House chief medical advisor Dr. Anthony Fauci said, “The revelation of the efficacy of this specific antiviral is obviously really excellent news.” “The corporation informed us last night that they will be submitting their data to the FDA as soon as possible.”
“The FDA will evaluate the data in their typical, very efficient and effective manner, and then it will be taken from there,” Fauci added.
The following is an excerpt from Politico’s coverage on the medical trial’s progress:
Within five days of beginning the research, all 775 patients included in Merck’s interim analysis had tested positive for mild or moderate Covid-19. Furthermore, all trial participants were unvaccinated and had at least one condition that elevated their likelihood of developing severe Covid-19, such as being over 60 years old, being obese, or having diabetes or heart disease.
Through the 29th day of the study, little over 7% of patients who took the medicine, which is administered twice a day for five days, had been hospitalized. According to Merck, roughly 14% of the placebo group was hospitalized or died.
During that time, no deaths were reported in patients on molnupiravir, whereas eight people taking the placebo died.
The FDA and Merck have agreed to put the trial on hold in order to get Emergency Use Authorization.
According to CNBC, the EUA application:
Merck and Ridgeback Biotherapeutics said on Friday that they have created a medication that reduces the risk of hospitalization or death in patients with mild or moderate Covid by around half.
Following “compelling results” in clinical trials, the businesses plan to seek emergency approval for the antiviral Covid therapy.
The medicine, molnupiravir, is taken orally and acts by preventing the coronavirus from replicating inside the body.
According to an interim review of a phase 3 study, 7.3 percent of individuals treated with molnupiravir were admitted to the hospital within 29 days. By day 29, 14.1 percent of individuals who got a placebo had been hospitalized or died. Within the 29-day period, no deaths were observed in molnupiravir-treated individuals, but eight deaths were reported in placebo-treated patients.
Merck, of course, is the maker of Ivermectin, which has been slandered in the media despite the CDC’s recommendation of it as an anti-parasitic medicine for human use in 2019. Molnupiravir and ivermectin are chemically very different. Ivermectin, on the other hand, is relatively inexpensive to buy.
Merck released a warning in February.
For proof of efficacy and safety, company experts continue to carefully review the outcomes of all available and emerging studies of ivermectin for the treatment of COVID-19. It’s worth noting that our research has found the following:
There is no scientific basis for a prospective therapeutic impact against COVID-19 based on pre-clinical studies; there is no meaningful evidence for clinical activity or clinical efficacy in COVID-19 disease patients; and the majority of studies have a concerning lack of safety data.
We do not feel that the available data supports the safety and efficacy of ivermectin in doses or populations other than those listed in the regulatory agency-approved prescription information.
“Moderate-certainty evidence suggests that employing ivermectin, considerable reductions in COVID-19 mortality are likely. The study concluded that using ivermectin early in the clinical course could lower the number of people who advance to severe illness. “Ivermectin’s evident safety and low cost suggest that it will have a big impact on the global SARS-CoV-2 pandemic.”
Ivermectin has lately been credited with playing a key part in India’s recovery from Covid, despite the country’s poor immunization rate. It was, however, recently withdrawn from India’s Covid medical treatment routine.